RepublicanBill · H.R. 1864· House(119-HR-1864)

Risky Research Review Act

Rep. Griffith
Age: 68 years
Virginia
Introduced
3/5/2025
Last activity
3/5/2025 — Referred to the Committee on Science, Space, and Technology, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsored by
H. Griffith
Cosponsors
None
Health
  1. Introduced
  2. In Committee

What this bill would do

This bill establishes the Life Sciences Research Security Board as an independent agency within the Executive Branch. The Board is tasked with reviewing proposed Federal funding for high-risk life sciences research, including gain of function and dual use research of concern. It holds the authority to issue binding determinations on whether an agency may award funding for such research. Members of the Board are appointed by the President and include scientists, national security experts, and biosafety experts. The legislation also outlines specific agency procedures for attestation, certification, and notification of research changes.

Yes· 3 of 4

  • Does this better protect air, water and wildlife?+1

    The bill provides oversight to protect agricultural crops and other plants from high-consequence pathogens.

  • Does this make what the government does easier for the public to see?+1

    The bill requires regular reports to Congress and public publication of many Board determinations and violations.

  • Does this make health care easier to get in general?+1

    The oversight of high-risk research aims to protect public health and prevent the spread of dangerous pathogens.

The opposite· 3 of 6

  • Would business owners be better off under this?-3

    Research entities face increased compliance burdens, mandatory disclosures, and strict agency consent requirements for subcontracts.

  • Does this put more money into scientific research?-2

    The bill introduces new mandatory review processes and potential funding suspensions for high-risk life sciences research.

  • Would union members be better off under this?-1

    The potential for research pauses and funding disruptions could negatively impact workers in the life sciences industry.